DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Mounjaro (tirzepatide 2.5–15mg) costs From $499/month via TrumpRx → LillyDirect cash-pay, $25/month with insurance + savings card, or up to $1,112/month list retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
| Channel | Source | |
|---|---|---|
Cash-pharmacy + savings card Commercially insured with coverage — manufacturer copay card (GoodRx/SingleCare style discount otherwise). | $25 with commercial insurance + savings cardBest value | Manufacturer savings card terms |
With insurance (covered, after PA) Commercial plan that covers the drug after prior authorization — copay depends on your tier. | $25/month – $150/month | Plan formulary copay tiers |
Compounded (telehealth, where legal) Cash-pay via 503A pharmacy telehealth. Not FDA-approved as the brand — regulatory wind-down ongoing. | $249–$349/month | Compounded tirzepatide via telehealth |
Manufacturer cash — TrumpRx → LillyDirect cash-pay Anyone with a valid prescription who pays cash — no insurance required, valid in all 50 states. | From $499/monthLowest | LillyDirect |
Retail / list (cash, no programs) Walk-in pharmacy price with no insurance, savings card, or manufacturer program. | $1,112/month listList price | WAC / pharmacy list, LoseLab pricing desk |
We’ll email you the day it gets cheaper — no spam, unsubscribe anytime.
Mounjaro's list price is about $1,112/month. Cash buyers can get it from $499/month through TrumpRx, which routes the order to LillyDirect; commercially insured patients whose plan does not cover it can pay as low as $499 with the Lilly savings card.
Lowest observed cash-pay ranges from our state cost matrix. Where you fill changes the price.
Mounjaro is FDA-approved for type 2 diabetes only. T2D coverage is widespread on commercial plans with PA — typically requiring metformin trial and A1C documentation. Copays range $25–$150/month. Off-label weight-loss prescribing is heavily audited in 2026 — for weight loss, use Zepbound.
Two Mounjaro programs: (1) Lilly savings card — $25/month T2D copay with commercial insurance, valid 12 months; (2) cash-pay — from $499/month via TrumpRx/LillyDirect. Cardiovascular indication coverage continues to expand for established CVD patients.
Medicare Part D covers Mounjaro for T2D under standard pharmacy benefit. PA required. Off-label weight-loss prescribing not covered.
Medicaid covers Mounjaro for T2D in most states. PA criteria typical (A1C documentation, metformin step). Weight-loss-only prescribing not covered.
Same tirzepatide. FDA-approved for weight loss. Better PA approval rate for non-T2D patients because the prescribing matches the FDA indication.
Different molecule. Lower A1C reduction in SURPASS-2 head-to-head (1.9% vs Mounjaro 2.3%) but more cardiovascular outcomes data.
$249–$349/month — same active ingredient, not FDA-approved. 503A pharmacy compounding, regulatory wind-down ongoing.
Mounjaro out-of-pocket cost ranges $25/month (T2D + savings card) to about $1,112/month (list price). For T2D patients, the savings card path is the right answer. For weight loss, switch to Zepbound — LillyDirect vials run $299–$449/month by dose.
Read full Mounjaro review →Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.